Full Press Release Details
Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
(Scrip Code: 500124)
Stock Exchange Inc.(Stock Code: RDY)
find enclosed a notification titled "Dr. Reddy's to release Q1 results on July 26th, 2023
call slated for July 26th @ 7:30 PM IST / 10:00 AM EDT."
for your information.
Dr. Reddy's Laboratories Limited
| /s/ K Randhir Singh | |
| K Randhir Singh | |
| Company Secretary, Compliance Officer and Head-CSR |
| CONTACT | ||||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS | ||
| 8-2-337, Road No. 3, Banjara Hills, | RICHA PERIWAL | USHA IYER | ||
| Hyderabad - 500034. Telangana, India. | RICHAPERIWAL@DRREDDYS.COM | ushaiyer@drreddys.com |
Reddy's to release Q1 results on July 26th, 2023
call slated for July 26th @ 7:30 PM IST / 10:00 AM EDT
Dr. Reddy's Laboratories
Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the first quarter ended June 30th,
2023 on Wednesday, July 26th, 2023 after the Board Meeting.
| Event | Date and Time | Medium | ||
| Release of financial results | July 26 th , after the Board Meeting | Stock Exchange, Media, Company website, Business wire, Email | ||
| Press meet presentation | Will be available on the Company's website | Company's website www.drreddys.com | ||
| Earnings Call | July 26 th , 7:30 PM IST / 10:00 AM EDT | Hosted by the Company | ||
| (Details below) | ||||
| Playback of Earnings Call | After the earnings call till Aug 2 nd , 2023 | Details below | ||
| Transcript of the Earnings call | Will be available on the Company's website | Company's website www.drreddys.com |
the release, the management of the Company will host Its earnings call to discuss the Company's financial performance. (Dial
In and other details given below)
play back will be available after the earnings call, till Aug 2nd, 2023. For play back dial in phone No: +91 22 7194 5757,
and Playback Code is 75822.
Join with DiamondPass
the below link and join without waiting for the operator.
| Option 2: Join through below Dial-In Numbers | |
| Universal Access Number: | +91 22 6280 1219 |
| +91 22 7115 8120 | |
| International Toll Free Number: | USA: 1 866 746 2133 |
| UK: 0 808 101 1573 | |
| Singapore: 800 101 2045 Hong Kong: 800 964 448 |
password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before
and during the call.
Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical
company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines.
Driven by our purpose of Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics,
branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology,
pain management and dermatology. Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe.
As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses
of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current
ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For
more information, log on to: www.drreddys.com.
This press release may include statements of future expectations and other forward-looking statements that are based on the management's
current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events
to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason
of context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults
, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in
the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues,
and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic
downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and
(vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed
under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year
ended March 31, 2023. The company assumes no obligation to update any information contained herein.